Sequence-based drug design as a concept in computational drug design
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Drug development based on target proteins has been a successful approach in recent decades. However, the conventional structure-based drug design (SBDD) pipeline is a complex, human-engineered process with multiple independently optimized steps. Here, we propose a sequence-to-drug concept for computational drug design based on protein sequence information by end-to-end differentiable learning. We validate this concept in three stages. First, we design TransformerCPI2.0 as a core tool for the concept, which demonstrates generalization ability across proteins and compounds. Second, we interpret the binding knowledge that TransformerCPI2.0 learned. Finally, we use TransformerCPI2.0 to discover new hits for challenging drug targets, and identify new target for an existing drug based on an inverse application of the concept. Overall, this proof-of-concept study shows that the sequence-to-drug concept adds a perspective on drug design. It can serve as an alternative method to SBDD, particularly for proteins that do not yet have high-quality 3D structures available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
BERT: Pre-training of Deep Bidirectional Transformers for Language Understanding
Devlin, J., Chang, M.-W., Lee, K., & Toutanova, K. (2018) · arXiv · doi:10.48550/arxiv.1810.04805 · Cited by 73,173
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
Accurate prediction of protein structures and interactions using a 3-track network
Baek, M., DiMaio, F., Anishchenko, I., Dauparas, J., Ovchinnikov, S., Lee, G. R., Wang, J., Cong, Q., Kinch, L. N., Schaeffer, R. D., et al. (2021) · doi:10.1101/2021.06.14.448402 · Cited by 5,549 · cited 1×
“Two substrates of SPOP are phosphatase and tensin homolog (PTEN) and dual speci fi city phosphatase 7 (DUSP7) 47 .”
Highly accurate protein structure prediction for the human proteome
Tunyasuvunakool, K., Adler, J., Wu, Z., Green, T., Zielinski, M., Žídek, A., Bridgland, A., Cowie, A., Meyer, C., Laydon, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03828-1 · Cited by 3,025
Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking.
Mysinger, M. M., Carchia, M., Irwin, J. J., & Shoichet, B. K. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300687e · Cited by 2,412 · cited 1×
“We used the benchmark dataset DUD-E set 30 and DEKOIS2.”
Research works printed but not linked: 54
- Gorgulla, C. et al. An open-source drug discovery platform enables ultra-large virtual screens. Nature 580, 663–668 (2020). · DOI · Paper page
- Zheng, M. et al. Computational chemical biology and drug design: facilitating protein structure, function, and modulation studies. Med. Res. Rev. 38, 914–950 (2018). · DOI
- Zheng, M. et al. Computational methods for drug design and discovery: focus on China. Trends Pharmacol. Sci. 34, 549–559 (2013). · DOI
- Tong, A. B. et al. Could AlphaFold revolutionize chemical therapeutics? Nat. Struct. Mol. Biol. 28, 771–772 (2021). · DOI · Paper page
- Mullard, A. What does AlphaFold mean for drug discovery. Nat. Rev. Drug Discov. 20, 725–727 (2021). · DOI · Paper page
- Kitchen, D. B., Decornez, H., Furr, J. R. & Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov. 3, 935–949 (2004). · DOI · Paper page
- Stank, A., Kokh, D. B., Fuller, J. C. & Wade, R. C. Protein binding pocket dynamics. Acc. Chem. Res. 49, 809–815 (2016). · DOI · Paper page
- Zhu, T. et al. Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. J. Med. Chem. 56, 6560–6572 (2013). · DOI · Paper page
- Nguyen, T. et al. GraphDTA: predicting drug–target binding affinity with graph neural networks. Bioinformatics 37, 1140–1147 (2020). · DOI · Paper page
- Li, S. et al. MONN: a multi-objective neural network for predicting compound-protein interactions and affinities. Cell Syst. 10, 308–322.e311 (2020). · DOI · Paper page
- Ozturk, H., Ozgur, A. & Ozkirimli, E. DeepDTA: deep drug-target binding affinity prediction. Bioinformatics 34, i821–i829 (2018). · DOI · Paper page
- Karimi, M., Wu, D., Wang, Z. & Shen, Y. DeepAffinity: interpretable deep learning of compound–protein affinity through unified recurrent and convolutional neural networks. Bioinformatics 35, 3329–3338 (2019). · DOI · Paper page
- Zhao, Q., Zhao, H., Zheng, K. & Wang, J. HyperAttentionDTI: improving drug–protein interaction prediction by sequence-based deep learning with attention mechanism. Bioinformatics 38, 655–662 (2021). · DOI · Paper page
- Yang, Z., Zhong, W., Zhao, L. & Chen, C. Y.-C. ML-DTI: mutual learning mechanism for interpretable drug–target interaction prediction. J. Phys. Chem. Lett. 12, 4247–4261 (2021). · DOI
- Kim, Q., Ko, J.-H., Kim, S., Park, N. & Jhe, W. Bayesian neural network with pretrained protein embedding enhances prediction accuracy of drug-protein interaction. Bioinformatics 37, 3428–3435 (2021). · DOI
- Cai, T. et al. MSA-regularized protein sequence transformer toward predicting genome-wide chemical-protein interactions: application to GPCRome deorphanization. J. Chem. Inf. Model. 61, 1570–1582 (2021). · DOI
- Huang, K., Xiao, C., Glass, L. M. & Sun, J. MolTrans: molecular interaction transformer for drug–target interaction prediction. Bioinformatics 37, 830–836 (2021). · DOI · Paper page
- Bauer, M. R., Ibrahim, T. M., Vogel, S. M. & Boeckler, F. M. Evaluation and optimization of virtual screening workflows with DEKOIS 2.0 – a public library of challenging docking benchmark sets. J. Chem. Inf. Model. 53, 1447–1462 (2013). · DOI · Paper page
- Bender, A. & Glen, R. C. A discussion of measures of enrichment in virtual screening: comparing the information content of descriptors with increasing levels of sophistication. J. Chem. Inf. Model. 45, 1369–1375 (2005). · DOI · Paper page
- Cunningham Brian, C. & Wells James, A. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244, 1081–1085 (1989). · DOI · Paper page
- Cote, B. et al. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg. Med. Chem. Lett. 24, 917–922 (2014). · DOI
- Wensing, A. M. et al. 2019 update of the drug resistance mutations in HIV-1. To.p Antivir. Med. 27, 111–121 (2019).
- Khan, N. H. et al. HIV drug resistance mutations in patients with HIV and HIV-TB coinfection after failure of first-line therapy: a prevalence study in a resource-limited setting. J. Int. Assoc. Provid. AIDS Care 18, 2325958219849061 (2019). · doi:10.1177/2325958219849061
- Lai, M.-T. et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 58, 1652–1663 (2014). · DOI
- Smith, S. J. et al. Rilpivirine and doravirine have complementary efficacies against NNRTI-resistant HIV-1 mutants. J. Acquir. Immune Defic. Syndr. 72, 485–491 (2016). · DOI
- Stumpfe, D., Hu, Y., Dimova, D. & Bajorath, J. R. Recent progress in understanding activity cliffs and their utility in medicinal chemistry: miniperspective. J. Med. Chem. 57, 18–28 (2014). · DOI · Paper page
- Bajorath, J. Duality of activity cliffs in drug discovery. Expert Opin. Drug Discov. 14, 517–520 (2019). · DOI
- Abula, A. et al. Substitution effect of the trifluoromethyl group on the bioactivity in medicinal chemistry: statistical analysis and energy calculations. J. Chem. Inf. Model. 60, 6242–6250 (2020). · DOI
- Xu, L. et al. BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. Nature 425, 316–321 (2003). · DOI · Paper page
- Guo, Z.-Q. et al. Small-molecule targeting of E3 ligase adaptor SPOP in kidney cancer. Cancer Cell 30, 474–484 (2016). · DOI
- Li, G. et al. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell 25, 455–468 (2014). · DOI · Paper page
- Chappell, J., Sun, Y., Singh, A. & Dalton, S. MYC/MAX control ERK signaling and pluripotency by regulation of dual-specificity phosphatases 2 and 7. Genes Dev. 27, 725–733 (2013). · DOI
- Ariza, A. et al. Study of protein haptenation by amoxicillin through the use of a biotinylated antibiotic. PLoS ONE 9, e90891 (2014). · DOI
- Mora-Ochomogo, M. & Lohans, C. T. β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates. RSC Med. Chem. 12, 1623–1639 (2021). · DOI · Paper page
- Zhang, X. & Jia, Y. Recent advances in β-lactam derivatives as potential anticancer agents. Curr. Top. Med. Chem. 20, 1468–1480 (2020). · doi:10.2174/1568026620666200309161444
- Kamath, A. & Ojima, I. Advances in the chemistry of β-lactam and its medicinal applications. Tetrahedron 68, 10640–10664 (2012). · DOI · Paper page
- Palm, K., Stenberg, P., Luthman, K. & Artursson, P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14, 568–571 (1997). · DOI · Paper page
- Spugnini, E. & Fais, S. Proton pump inhibition and cancer therapeutics: a specific tumor targeting or it is a phenomenon secondary to a systemic buffering? Semin. Cancer Biol. 43, 111–118 (2017). · DOI
- Singh, S. R. et al. The lipolysis pathway sustains normal and transformed stem cells in adult Drosophila. Nature 538, 109–113 (2016). · DOI
- Wang, G. et al. Arf1-mediated lipid metabolism sustains cancer cells and its ablation induces anti-tumor immune responses in mice. Nat. Commun. 11, 220 (2020). · DOI
- D’Souza-Schorey, C. & Chavrier, P. ARF proteins: roles in membrane traffic and beyond. Nat. Rev. Mol. Cell Biol. 7, 347–358 (2006). · DOI · Paper page
- Olbe, L., Carlsson, E. & Lindberg, P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat. Rev. Drug Discov. 2, 132–139 (2003). · DOI · Paper page
- Bühlmann, S. & Reymond, J.-L. ChEMBL-likeness score and database GDBChEMBL. Front. Chem. 8, 46 (2020). · DOI
- Chevillard, F. & Kolb, P. SCUBIDOO: a large yet screenable and easily searchable database of computationally created chemical compounds optimized toward high likelihood of synthetic tractability. J. Chem. Inf. Model. 55, 1824–1835 (2015). · DOI · Paper page
- Massarotti, A., Brunco, A., Sorba, G. & Tron, G. C. ZINClick: a database of 16 million novel, patentable, and readily synthesizable 1,4-disubstituted triazoles. J. Chem. Inf. Model. 54, 396–406 (2014). · DOI
- Visini, R., Awale, M. & Reymond, J.-L. Fragment database FDB-17. J. Chem. Inf. Model. 57, 700–709 (2017). · DOI
- Yang, T. et al. DrugSpaceX: a large screenable and synthetically tractable database extending drug space. Nucleic Acids Res. 49, D1170–D1178 (2021). · DOI
- Grygorenko, O. O. et al. Generating multibillion chemical space of readily accessible screening compounds. iScience 23 (2020). · DOI · Paper page
- Bepler, T. & Berger, B. Learning protein sequence embeddings using information from structure. Preprint at https://arxiv.org/abs/1902.08661 (2019). · arXiv
- Kipf, T. N. & Welling, M. Semi-supervised classification with graph convolutional networks. Preprint at https://arxiv.org/abs/1609.02907 (2016). · arXiv
- Liu, L. et al. On the variance of the adaptive learning rate and beyond. Preprint at https://arxiv.org/abs/1908.03265 (2019). · arXiv
- Gaulton, A. et al. The ChEMBL database in 2017. Nucleic Acids Res. 45, D945–D954 (2017). · DOI · Paper page
- Papadatos, G., Gaulton, A., Hersey, A. & Overington, J. P. Activity, assay and target data curation and quality in the ChEMBL database. J. Comput. Aided Mol. Des. 29, 885–896 (2015). · DOI · Paper page
- Kramer, C., Kalliokoski, T., Gedeck, P. & Vulpetti, A. The experimental uncertainty of heterogeneous public Ki data. J. Med. Chem. 55, 5165–5173 (2012). · DOI · Paper page
Cited by
Artificial intelligence in drug development
Zhang, K., Yang, X., Wang, Y., Yu, Y., Huang, N., Li, G., Li, X., Wu, J. C., & Yang, S. (2025) · Nature Medicine · doi:10.1038/s41591-024-03434-4 · Cited by 498
Self-citationG protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 491
Self-citationCao, D., Chen, M., Zhang, R., Wang, Z., Huang, M., Yu, J., Jiang, X., Fan, Z., Zhang, W., Zhou, H., et al. (2025) · Nature Methods · doi:10.1038/s41592-024-02516-y · Cited by 106
Self-citationIntegrating Computational Design and Experimental Approaches for Next-Generation Biologics
Son, A., Park, J., Kim, W., Lee, W., Yoon, Y., Ji, J., & Kim, H. (2024) · Biomolecules · doi:10.3390/biom14091073 · Cited by 29
BioStructNet: Structure-Based Network with Transfer Learning for Predicting Biocatalyst Functions
Wang, X., Zhou, J., Mueller, J., Quinn, D., Carvalho, A., Moody, T. S., & Huang, M. (2025) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.4c01391 · Cited by 7
Metadata
- Authors
- Chen, L., Fan, Z., Chang, J., Yang, R., Hou, H., Guo, H., Zhang, Y., Yang, T., Zhou, C., Sui, Q., Chen, Z., Zheng, C., Hao, X., Zhang, K., Cui, R., Zhang, Z., Ma, H., Ding, Y., Zhang, N., Lu, X., Luo, X., Jiang, H., Zhang, S., & Zheng, M.
- Venue
- Nature Communications
- Published
- 2023-07-14
- Volume
- 14
- Issue
- 1
- Pages
- 4217-4217
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W4384296638
- Cited by
- 124
- References
- 22
- FWCI
- 16.32
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sequence-based drug design as a concept in computational drug design. https://app.cochat.ai/papers/10.1038/s41467-023-39856-w
- The paper
- Chen, L., Fan, Z., Chang, J., Yang, R., Hou, H., Guo, H., Zhang, Y., Yang, T., Zhou, C., Sui, Q., Chen, Z., Zheng, C., Hao, X., Zhang, K., Cui, R., Zhang, Z., Ma, H., Ding, Y., Zhang, N., . . . Zheng, M. (2023). Sequence-based drug design as a concept in computational drug design. Nature Communications. https://doi.org/10.1038/s41467-023-39856-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.